Practical and cost-effective model to build and sustain a cardio-oncology program.
Cardio-oncology
Cardiology
Care delivery model
Oncology
Screening
Journal
Cardio-oncology (London, England)
ISSN: 2057-3804
Titre abrégé: Cardiooncology
Pays: England
ID NLM: 101689938
Informations de publication
Date de publication:
2020
2020
Historique:
received:
17
04
2020
accepted:
03
07
2020
entrez:
22
7
2020
pubmed:
22
7
2020
medline:
22
7
2020
Statut:
epublish
Résumé
Cardio-Oncology (CO) is a new subspecialty that thrives mostly in large academic quaternary centers. This study describes how to establish a successful cardio-oncology program, with limited resources, in order to effectively manage the unique care required by this patient population. Clinical data was collected from 25 consecutive months. There were four foundational elements to establish a CO program: 1. Clinical program: integrating staff and resources from the Heart and Vascular, and Cancer Centers; 2. Education Program: establishing a platform to educate/advocate with respect to CO; 3. Engagement with professional societies: active engagement allowed for the successful establishment of the proposed CO program; and 4. Research program: establishing data collection modalities/cooperation with other institutions. 474 consecutive patients were treated by our CO program during the first 25 months of operation. Clinical data, information about cancer treatment, cardiovascular co morbidities, cardiac testing and impact of CO management are reported. A successful CO program can be established utilizing existing resources without the need for significant additional assets. Integration with professional societies, advocacy, education and research, provide a platform for learning and growth. This model improves access to care and can be reproduced in a variety of settings.
Sections du résumé
BACKGROUND
BACKGROUND
Cardio-Oncology (CO) is a new subspecialty that thrives mostly in large academic quaternary centers. This study describes how to establish a successful cardio-oncology program, with limited resources, in order to effectively manage the unique care required by this patient population.
METHODS
METHODS
Clinical data was collected from 25 consecutive months. There were four foundational elements to establish a CO program: 1. Clinical program: integrating staff and resources from the Heart and Vascular, and Cancer Centers; 2. Education Program: establishing a platform to educate/advocate with respect to CO; 3. Engagement with professional societies: active engagement allowed for the successful establishment of the proposed CO program; and 4. Research program: establishing data collection modalities/cooperation with other institutions.
RESULTS
RESULTS
474 consecutive patients were treated by our CO program during the first 25 months of operation. Clinical data, information about cancer treatment, cardiovascular co morbidities, cardiac testing and impact of CO management are reported.
CONCLUSIONS
CONCLUSIONS
A successful CO program can be established utilizing existing resources without the need for significant additional assets. Integration with professional societies, advocacy, education and research, provide a platform for learning and growth. This model improves access to care and can be reproduced in a variety of settings.
Identifiants
pubmed: 32690995
doi: 10.1186/s40959-020-00063-x
pii: 63
pmc: PMC7363993
doi:
Types de publication
Journal Article
Langues
eng
Pagination
9Informations de copyright
© The Author(s) 2020.
Déclaration de conflit d'intérêts
Competing interestsThe authors declare they have no competing interests.
Références
J Am Coll Cardiol. 2010 Jan 19;55(3):213-20
pubmed: 20117401
CA Cancer J Clin. 2018 Jan;68(1):7-30
pubmed: 29313949
N Engl J Med. 2013 Mar 21;368(12):1154-6
pubmed: 23514294
J Clin Oncol. 2017 Mar 10;35(8):893-911
pubmed: 27918725
Eur Heart J. 2016 Jun 1;37(21):1671-80
pubmed: 26903532
J Clin Oncol. 2005 Nov 1;23(31):7820-6
pubmed: 16258084
J Am Coll Cardiol. 2015 Sep 8;66(10):1160-78
pubmed: 26337996
Eur Heart J. 2019 Dec 21;40(48):3898-3900
pubmed: 31761931
J Am Coll Cardiol. 2015 Sep 8;66(10):1193-7
pubmed: 26337999
J Telemed Telecare. 2020 Jun;26(5):309-313
pubmed: 32196391
JMIR Public Health Surveill. 2020 Apr 2;6(2):e18810
pubmed: 32238336
J Am Coll Cardiol. 2018 Apr 24;71(16):1755-1764
pubmed: 29567210
Breast Cancer Res Treat. 2014 Feb;144(1):163-70
pubmed: 24469642
Eur Heart J. 2019 Dec 21;40(48):3889-3897
pubmed: 31761945
J Am Coll Cardiol. 2019 May 7;73(17):2226-2235
pubmed: 31047011
Curr Treat Options Cardiovasc Med. 2014 Jun;16(6):315
pubmed: 24748018
Cardiol Rev. 2018 May/Jun;26(3):122-129
pubmed: 29077585
J Am Coll Cardiol. 2014 Jul 1;63(25 Pt A):2751-68
pubmed: 24703918
Cleve Clin J Med. 2016 Dec;83(12):914-922
pubmed: 27938516
J Clin Oncol. 2017 Mar 10;35(8):870-877
pubmed: 27893331
J Am Coll Cardiol. 2013 Jan 8;61(1):77-84
pubmed: 23199515
Eur Heart J. 2016 Sep 21;37(36):2768-2801
pubmed: 27567406
Oncol Rev. 2017 Jul 18;11(2):340
pubmed: 28781723
J Am Coll Cardiol. 2018 Jul 10;72(2):228-232
pubmed: 29976296
J Oncol. 2015;2015:671232
pubmed: 26300917
J Card Fail. 2016 Jun;22(6):465-71
pubmed: 27038642
Eur Heart J Cardiovasc Imaging. 2014 Oct;15(10):1063-93
pubmed: 25239940
J Clin Oncol. 2019 Aug 1;37(22):1946-1955
pubmed: 31188726
Cancer Epidemiol Biomarkers Prev. 2016 Jul;25(7):1029-36
pubmed: 27371756
J Am Coll Cardiol. 2019 Jun 11;73(22):2859-2868
pubmed: 31171092
J Clin Oncol. 2010 Sep 1;28(25):3910-6
pubmed: 20679614
J Am Coll Cardiol. 2018 May 22;71(20):2281-2290
pubmed: 29540327
J Am Coll Cardiol. 2015 Jun 30;65(25):2739-46
pubmed: 26112199
Curr Oncol Rep. 2019 Mar 5;21(4):29
pubmed: 30834998
Cardiol J. 2012;19(5):453-8
pubmed: 23042307
Lancet Oncol. 2018 Dec;19(12):1579-1589
pubmed: 30442497
N Engl J Med. 2013 Mar 14;368(11):987-98
pubmed: 23484825